

# Spitz melanoma is a distinct subset of spitzoid melanoma

---

Raghavan, Shyam S.; Peternel, Sandra; Mully, Thaddeus W.; North, Jeffrey P.; Pincus, Laura B.; LeBoit, Philip E.; McCalmont, Timothy H.; Bastian, Boris C.; Yeh, Iwei

Source / Izvornik: **Modern Pathology, 2020, 33, 1122 - 1134**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1038/s41379-019-0445-z>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:631884>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom](#).

Download date / Datum preuzimanja: **2025-01-31**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)





Published in final edited form as:

*Mod Pathol.* 2020 June ; 33(6): 1122–1134. doi:10.1038/s41379-019-0445-z.

## Spitz Melanoma is a Distinct Subset of Spitzoid Melanoma

Shyam Raghavan, MD<sup>1</sup>, Sandra Peternel, MD<sup>2,3</sup>, Thaddeus W. Mully, MD<sup>2</sup>, Jeffrey P. North, MD<sup>2</sup>, Laura B. Pincus, MD<sup>2</sup>, Philip E. LeBoit, MD<sup>2</sup>, Timothy H. McCalmont, MD<sup>2</sup>, Boris C. Bastian, MD, PhD<sup>2</sup>, Iwei Yeh, MD, PhD<sup>2</sup>

<sup>1</sup>Department of Pathology, Stanford University, Stanford, CA

<sup>2</sup>Departments of Pathology and Dermatology, University of California San Francisco, San Francisco, CA

<sup>3</sup>Department of Dermatovenereology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia

### Abstract

Melanomas that have histopathologic features that overlap with those of Spitz nevus are referred to as spitzoid melanomas. However, the diagnostic concept is used inconsistently and genomic analyses suggest it is a heterogeneous category. Spitz tumors, the spectrum of melanocytic neoplasms extending from Spitz nevi to their malignant counterpart Spitz melanoma, are defined in the 2018 WHO classification of skin tumors by the presence of specific genetic alterations such as a kinase fusions or *HRAS* mutations. It is unclear what fraction of ‘spitzoid melanomas’ defined solely by their histopathologic features belong to the category of Spitz melanoma or to other melanoma subtypes. We assembled a cohort of 25 spitzoid melanomas diagnosed at a single institution over an eight-year period and performed high coverage DNA sequencing of 480 cancer related genes. Transcriptome wide RNA sequencing was performed for select cases. Only 9 cases (36%) had genetic alterations characteristic of Spitz melanoma, including *HRAS* mutation or fusion involving *BRAF*, *ALK*, *NTRK1*, or *MAP3K8*. The remaining cases were divided into those with a MAPK activating mutation and those without. Both Spitz melanoma and spitzoid melanomas in which a MAPK activating mutation could not be identified tended to occur in younger patients on skin with little solar elastosis, infrequently harbored *TERT* promoter mutations, and had a lower burden of pathogenic mutations than spitzoid melanomas with non-Spitz MAPK activating mutations. The MAPK activating mutations identified affected non-V600 residues of *BRAF* as well as *NRAS*, *MAP2K1/2*, *NF1* and *KIT* while *BRAF* V600 mutations, the most common mutations in melanomas of the WHO low-CSD category, were entirely absent.

While the ‘spitzoid melanomas’ comprising our cohort were enriched for bona fide Spitz melanomas, the majority of melanomas fell outside of the genetically defined category of Spitz melanomas, indicating that histomorphology is an unreliable predictor of Spitz lineage.

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Corresponding Author: Iwei Yeh, MD, PhD, 1701 Divisadero St. Suite 280, San Francisco, CA 94143, **Telephone Number:** (415) 353-7989, **Fax Number:** (415) 353-7542.

Disclosure/Conflict of Interest

The authors declare no relevant disclosures or conflicts of interest.

## Introduction

Spitz nevi are composed of epithelioid to spindled melanocytes with abundant homogenous cytoplasm and large vesicular nuclei, and often display epidermal hyperplasia, clefts around and between melanocytes, Kamino bodies, and maturation with descent. They can have limited scatter of melanocytes into the upper levels of the epidermis<sup>1</sup>. They were first described by Sophie Spitz in 1948 as melanomas of childhood<sup>2</sup>. Clinically, they are most commonly encountered as rapidly growing lesions in children but can occur at any age<sup>1,3</sup>. Spitz tumor refers to the spectrum of melanocytic tumors with histopathologic features of Spitz nevus that ranges from benign to malignant. They may be challenging to classify as benign or malignant because histopathologic features that are commonly taken as indicators of malignancy such as nuclear atypia, scatter of melanocytes in the upper epidermis, poor maturation within the dermis, deep extension, and deep dermal mitoses are not uncommonly seen in Spitz tumors with benign biologic behavior<sup>4</sup>.

Recently, a broad spectrum of MAPK activating alterations have been identified in Spitz nevi that differ from those in other types of melanocytic nevi. These include activating point mutations in *HRAS* (often with copy number gain of mutant *HRAS*) and rearrangements involving the serine/threonine kinases *BRAF* and *MAP3K8* or the receptor tyrosine kinases (RTKs) *ROS1*, *ALK*, *NTRK1*, *NTRK3*, *RET*, *MET*, and *MERTK*<sup>5-13</sup> and occur in a mutually exclusive fashion with only one mutation in a given Spitz nevus. Despite comprehensive genetic profiling of many Spitz nevi for other oncogenes and tumor suppressors, additional concomitant oncogenic drivers have not been identified, suggesting that these mutations alone are capable of initiating the clonal expansion that results in a Spitz nevus. Early studies indicated that the histomorphologic features of Spitz nevi correspond with their initiating mutations to some degree<sup>14-16</sup>. Thus, the diverse spectrum of initiating mutations in Spitz tumors and the resulting variation in the clinical phenotype likely contributes to the diagnostic difficulty of Spitz tumors. In contrast, the initiating mutations in common acquired nevi are much more homogeneous with over 80% harboring *BRAF*V600E mutations<sup>17,18</sup>. While there have been a number of iterations of criteria to distinguish Spitz nevi from melanoma<sup>19</sup>, even their authors acknowledge their limitations.

The term spitzoid melanoma refers to histopathologically malignant tumors comprised of large epithelioid melanocytes resembling those found in Spitz nevi. Spitzoid melanoma is thus a purely morphology-based diagnosis, and prior studies have shown that many tumors classified as such have genetic hallmarks of melanomas of skin with low-cumulative sun-induced damage (low-CSD melanomas), such as *BRAF* and *NRAS* mutations and a high mutation burden with a UV signature. As Spitz nevi do not show activating *BRAF* or *NRAS* point mutations, spitzoid melanomas with these mutations are not genetically related to Spitz nevi. In one study, fusions involving *BRAF* or RTKs were identified in 41% of Spitz nevi, but only 13% of spitzoid melanomas<sup>7</sup>. In another study of six pediatric spitzoid melanomas, kinase fusions typical of Spitz nevi were identified in 5 cases<sup>20</sup>. Activating *BRAF* or *NRAS* mutations, which are typical of other melanomas were identified in 20–86% of spitzoid melanomas across various studies<sup>21-24</sup>. De Forno et al. did not identify *HRAS* mutation, found in a subset of Spitz tumors, in a cohort of 21 spitzoid melanomas and on this basis argued that spitzoid melanomas are not related to *HRAS*-mutated Spitz nevi<sup>25</sup>. Lazova et al.

performed exome sequencing of 27 spitzoid melanomas and *BRAF*V600 mutations were found in 37% and *NRAS* mutations in 15% of cases. Only one case (4%) had an *HRAS* mutation indicative of a Spitz lineage<sup>24</sup>. Gene fusions are not detectable by exome sequencing and thus could not be analyzed in this study. The majority of cases in this series also had a mutation burden comparable to low- and high-CSD melanomas.

Based on the observation that a considerable portion of spitzoid melanomas have the genetic hallmarks of other types of cutaneous melanomas, the 2018 WHO classification of skin tumors introduced the concept of Spitz melanoma (malignant Spitz tumor) as a melanoma subtype that not only has the morphologic features of Spitz tumors, but also has their genetic hallmarks, namely the distinct spectrum of MAPK activating alterations described above<sup>26</sup>. This is likely an important distinction, as clinical evidence suggests that tumors at the malignant end of the spectrum of Spitz tumors have a better prognosis than other types of cutaneous melanomas. This applies particularly to children, in whom spitzoid tumors with malignant histopathologic features less commonly metastasize with lethal outcome as compared to conventional melanomas<sup>27</sup>. Therefore, we have designated spitzoid melanomas in children as “spitzoid melanoma, childhood type” in our practice and provide a comment that although they have histopathologic features of malignancy, their risk for recurrence and death appears lower than for conventional (or ‘adult-type’) cutaneous melanoma.

Here we investigate what fraction of spitzoid melanomas in our practice fall into the newly defined entity Spitz melanoma, and analyze their clinical, histomorphologic and genetic features.

## Materials and Methods

### Case Selection and Histopathologic analysis

After approval from the institutional review board at the University of California, San Francisco, we searched our archives for melanomas diagnosed from 2010–2017 and annotated as having spitzoid features. Each case was re-reviewed by three pathologists (S.P., S.R., I.Y.) and only cases that were determined to have spitzoid cytomorphologic features by consensus and had archival tissue available for molecular analysis were included. Pathologic features such epidermal effacement and hyperplasia, ulceration, Kamino body formation, dermal mitoses, and cytology/pleomorphism were recorded for each case. Pigmentation was graded on a 0–4 scale as previously described<sup>28</sup>. Similarly, the extent of solar elastosis was graded on a previously developed scale<sup>29</sup>. Clinical follow-up data was obtained from a combination of chart review and patient outreach.

### DNA and RNA Extraction

Hematoxylin and eosin stained sections were used to guide tumor microdissection from formalin-fixed paraffin embedded (FFPE) sections of 10 µm in thickness. DNA and RNA extraction was performed using the QIAGEN Allprep DNA/RNA FFPE extraction kit (QIAGEN, Germantown, MD, p/n 80204).

## DNA Sequencing and Analysis

50–250 ng of DNA was prepared for sequencing using the KAPA Hyper Prep Kit (KAPA Biosciences, Wilmington, MA p/n KK8504) according to the manufacturer's instructions. Custom-designed bait libraries were used to target the coding regions of 480 genes (Supplementary Table 1). Select introns of kinases rearranged in melanocytic tumors (*ALK*, *BRAF*, *MET*, *NTRK1*, *NTRK3*, *RET*, *ROS1*, *PRKCA*) and the promoter region of *TERT* were also targeted. Sequencing was performed as paired-end 100bp reads on a HiSeq2500 (Illumina).

Sequence reads were mapped to the human genome (hg19) using the Burrows-Wheeler aligner (BWA)<sup>30</sup>. Recalibration of reads and variant calling were performed using the Genome Analysis Toolkit (GATK)<sup>31</sup> and FreeBayes<sup>32</sup>. Quality metrics were determined using Picard<sup>33</sup> (Supplementary Table 2). Three samples with coverage below 25x tumor-specific coverage were excluded from the study. Variant annotation was performed with Annovar<sup>34</sup>. Structural variant detection was performed with Delly<sup>35</sup> and reviewed by visual inspection in the Integrative Genomics Viewer<sup>36</sup>. Resulting fusion transcripts were predicted by joining the exons upstream and downstream from the genomic breakpoint. Genomic copy number assessment was performed with CNVkit<sup>37</sup> which uses off-target reads with adjustment of copy ratios for tumor fraction as estimated by THetA<sup>38</sup>.

We reviewed all alterations annotated as pathogenic or likely pathogenic in ClinVar<sup>39</sup>. We excluded variants with greater than 1% prevalence in the NHLBI GO Exome Sequencing Project<sup>40</sup> or 1000 Genomes Project<sup>41</sup> from further review as they likely represent benign germline polymorphisms. We classified truncating mutations in known tumor suppressors as pathogenic. For genes in which a cancer related pathogenic alteration was identified, we manually annotated all remaining variants of that gene as pathogenic, likely pathogenic, uncertain significance, and likely benign by literature review, using various databases as annotation resources (OMIM<sup>42</sup>, MyCancerGenome<sup>43</sup>). We determined the number of pathogenic copy number alterations in each case. Shallow deletions of a tumor suppressor accompanied by pathogenic alteration of that tumor suppressor was considered a pathogenic copy number alteration. Deep deletions of tumor suppressors were counted as two pathogenic alterations. Copy number increase of an oncogene was counted as one pathogenic alteration, whereas amplification was counted as two pathogenic alterations. We also counted copy loss of chromosome 9p without mutation in the remaining allele of *CDKN2A* as a pathogenic alteration, given the importance of this tumor suppressor in melanoma and reports of gene silencing by promoter hypermethylation.

## RNA Sequencing and Analysis

For the nine cases in which a pathogenic MAPK activating alteration was not identified by DNA sequencing, whole transcriptome RNA sequencing was performed. 170–400 ng of total RNA was prepared for sequencing using the KAPA stranded RNA-seq kit (KAPA Biosciences, Wilmington, MA, p/n KK8400) according to the manufacturer's instructions. Subsequently, exome capture was carried out using NimbleGen SeqCap EZ MedExome target enrichment probes (Roche, Basel, Switzerland, p/n 07681330001) following the manufacturer's protocol. Sequencing was performed on a NovaSeq 6000 system (Illumina

Inc, San Diego, CA) with 150-bp paired-end reads. Sequence reads were mapped to the reference human genome (hg19) using STAR<sup>44</sup> and fusions were identified by FusionCatcher<sup>45</sup> and verified by manual review.

### Statistical Analyses

A genetic dataset for cutaneous melanoma provided by the Cancer Genome Atlas (*Skin Cutaneous melanoma, TCGA*)<sup>46</sup> was downloaded from cBioPortal<sup>47,48</sup>, providing mutational data for 448 cases of cutaneous melanomas. Previous studies have identified kinase fusions in the TCGA<sup>49,50</sup>. The prevalence of mutations in the TCGA dataset was compared to that of our cohort by Fisher's exact test.

Pearson correlation was calculated between age, number of pathogenic mutations, and extent of solar elastosis (converting the scale from Landi et al. which ranges from 0 to 3+ to an numeric scale ranging from 1–11). The statistical significance of the differences between each group was calculated by two-sided t-test.

### Results

A total of 25 patients with spitzoid melanoma were included in this study (see Table 1 for summary of clinical and histologic features). For 19 patients, we received biopsies in formalin, and for the remaining six patients we received slides sent in consultation. Their average age was 43.8 years (range 4–80 years), including six patients 16 years of age or younger. Males and females were evenly represented. The spitzoid melanomas most commonly involved the extremities (64%, 16/25) and less commonly the head and neck (20%, 5/25) or the trunk (16%, 4/25). The average Breslow thickness was 2.1 mm (range 0.4 – 8.4 mm) and the mean diameter was 5.9 mm (range 2.2 – 9.8 mm). It should be noted that some melanomas were transected at the base of the biopsy, so the Breslow thickness could be underestimated.

The majority of tumors (n=23, 92%) were predominantly composed of large epithelioid melanocytes with abundant cytoplasm with a minority of spindled melanocytes. Two cases (8%) were composed exclusively of spindled melanocytes. Cytoplasmic melanin was identified in 19 cases (76%), with 8 tumors (32%) demonstrating strong (grade 3–4) pigmentation. Epidermal hyperplasia was present in 80% of cases. Kamino bodies were uncommon, identified in only two (8%) cases.

### Spitz melanomas

Two spitzoid melanomas contained *HRAS* hotspot mutations with gain of the mutant allele (8%). One occurred on the leg of a 50-year-old woman and there was also loss of chromosome 9 on which *CDKN2A* resides (case 14). In this case, p16 expression was absent by immunohistochemistry, suggesting inactivation of the remaining allele of *CDKN2A*. The other melanoma occurred on the arm of a 75 year-old-woman, and in addition to the *HRAS* mutation there was a three-codon deletion in *MAP2K1* (p.102\_104del), a known gain-of-function mutation<sup>51,52</sup> with a copy number gain of the mutant allele, a hemizygous truncating mutation in *ARID1A*, an amplification of *NOTCH2*, and homozygous deletion of *CDKN2A* (case 23). Both *HRAS*-mutated Spitz melanomas were predominantly intradermal



with a broad, horizontal silhouette and haphazardly arranged, thickened collagen bundles (Figure 1), similar to *HRAS*-mutated Spitz nevi<sup>5</sup>.

*BRAF* fusions were identified in two cases (8%). Case 12 occurred on the knee of a 47 year old woman and had an *NRF1-BRAF* fusion, similar to those reported in pleomorphic xanthoastrocytoma<sup>53</sup>, a *TERT* promoter hotspot mutation<sup>54,55</sup>, and a hemizygous *PTEN*<sup>G165R</sup> mutation<sup>56</sup> (Figure 2). Case 4 (included in a previous study of *BRAF* fusions in melanocytic tumors<sup>6</sup>) harbored a *SOX6-BRAF* fusion with focal amplification of the fusion gene. While additional pathogenic point mutations were not identified, there were multiple copy number aberrations, including gains of distal chromosome 1p, chromosomes 2, 12, 13, and 15 as well as copy number neutral loss of heterozygosity of chromosome 3.

Rearrangements affected the receptor tyrosine kinases (RTKs) *ALK* in two cases (8%) and *NTRK1* in one case (4%). Case 7 occurred on the thigh of a 23 year-old-female and contained a *DCTN1-ALK* fusion with loss of chromosome 9 and increased dermal mitoses (3/mm<sup>2</sup>) (Figure 3). Case 10 occurred on the leg of a 34 year-old-man and harbored a fusion of the 3' portion of *ALK* to an intergenic region of chromosome 11q, with a gain of the distal portion of *ALK* encoding the kinase domain, suggesting that a complex rearrangement resulted in an *ALK* kinase fusion as the oncogene in this case. The tumors with *ALK* rearrangements demonstrated fascicular nests of melanocytes as characteristic of Spitz nevi with *ALK* fusions<sup>14,15</sup>. A *TPM3-NTRK1* fusion was present in one case along with gain of chromosome 17 and loss of chromosome 5p upstream of *TERT* suggestive of a genomic rearrangement which altered *TERT* promoter or enhancer sequences, a mechanism of telomerase reactivation previously described in neuroblastoma<sup>57</sup>. This tumor contained rosette-like structures within the dermal component (Figure 4), a feature that is more common in Spitz nevi with *NTRK1* fusion<sup>16</sup>.

Rearrangements of *MAP3K8* were identified in 2 cases by RNA sequencing (8%). Case 2 demonstrated a *ZFP36L1-MAP3K8* fusion and occurred on the right arm of an 11-year-old girl and was notable for pigment rich epithelioid and spindle cells with some adnexal extension. Case 11 contained a *MAP3K8-SVIL* fusion and presented on the right thigh of a 55-year-old man and contained severely pleomorphic epithelioid cells with mild epidermal hyperplasia. Both cases also demonstrated bi-allelic loss of *CDKN2A* without other pathogenic alterations.

While *HRAS* mutations and *BRAF* or RTK fusions were identified in the Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) cohort<sup>46,49</sup>, these alterations occurred at greater prevalence in our cohort (P=0.0479 for *HRAS* mutation, P=0.00041 for fusions of *BRAF*, *NTRK1*, or *ALK*). The difference in prevalence of *MAP3K8* fusion was not statistically significant (P=0.0942).

### **Mutations activating the MAP-kinase pathway were present in half of spitzoid melanomas without Spitz nevus associated mutations**

Altogether, nine (36%) of the spitzoid melanomas were classified as Spitz melanoma due to the presence of an oncogenic alterations typical of Spitz tumors. Other MAP-kinase pathway activating alterations not associated with Spitz nevi were identified in another nine (36%)

spitzoid melanomas. Interestingly, we did not identify any *BRAF*<sup>V600</sup> mutations in our cohort. *BRAF*<sup>V600E</sup> is common in melanomas without chronic sun-induced damage (non-CSD) and was significantly underrepresented in our spitzoid melanomas as compared to the TCGA SKCM cohort ( $P=1.3 \times 10^{-6}$ ). This underrepresentation was not due to excluding cases that were positive by BRAF V600E immunohistochemistry. We identified a *BRAF*<sup>D594G</sup> mutation in a single case (case 19), which is a class 3 *BRAF* mutation that is considered weakly activating<sup>58</sup>. This tumor had a concomitant activating *MAP2K2*<sup>F57Y</sup> mutation<sup>59–61</sup>. *MAP2K2*, also known as *MEK2*, acts directly downstream of *BRAF* in the MAPK pathway, and the *MAP2K2* mutation likely cooperates with the class 3 *BRAF* mutation. This tumor also had a hotspot mutation in the promoter of *TERT* and an activating *EZH2*<sup>Y646N</sup> mutation<sup>62</sup>. Histopathologically, this tumor contained large epithelioid cells with a high mitotic index and severe nuclear pleomorphism (Figure 5).

*NRAS* hotspot mutations were identified in five of cases (20%), at a similar prevalence as in the SKCM cohort of TCGA. It included a melanoma on the helix of the ear of a 16-year-old boy (case 6, Figure 6) with an *NRAS*<sup>Q61H</sup> mutation that underwent secondary amplification as the sole detected pathogenic mutation. In case 25, the *NRAS*<sup>Q61H</sup> mutation occurred in combination with an activating *CTNNB1*<sup>G34I</sup> mutation, a *TERT* promoter mutation, and *IDH1*<sup>R132C</sup> and *NFKBIE*<sup>G41E</sup> mutations<sup>63–65</sup>. This spitzoid melanoma also demonstrated a minor small cell component, which did not demonstrate the strong and uniform beta-catenin staining indicative of *CTNNB1* mutation observed in the majority of the melanoma. This finding suggests that the *CTNNB1* mutation arose later in melanoma progression resulting in the epithelioid cytomorphology present in the majority of the melanoma (Supplementary Figure 1).

Bi-allelic loss of *NFI* occurred in two (8%) cases, in combination with *NRAS*<sup>G12D</sup> in one case (case 17). Activating *KIT*<sup>L576P</sup> and *MAP2K1*<sup>E203K</sup> mutations were identified in the absence of additional MAPK pathway activating mutations in one case each<sup>66,67</sup>.

In the remaining seven (28%) of cases, no mutations in MAP-kinase pathway were identified. This included an unpigmented epithelioid cell tumor with a *CRTC1-TRIM11* fusion, typical for a new class of tumors that bear resemblance to clear cell sarcoma<sup>68</sup>, on the cheek of a 13-year-old girl (case 5, Supplementary Figure 2).

### Subclasses of spitzoid melanoma

A summary of the pathogenic mutations identified in our series is presented in Figure 7A. We identified three genetic subcategories in our series: 1) Spitz melanoma, 2) spitzoid melanoma without identified MAPK activating mutations and 3) spitzoid melanoma non-Spitz MAPK activating mutations. The latter tended to occur in older patients and arose in skin with higher degrees of solar elastosis and had more pathogenic alterations (Figure 7B, Supplemental Figure 3).

Mutations in the promoter of *TERT* are present in ~70% of cutaneous melanomas and are associated with worse prognosis in both conventional and spitzoid melanoma<sup>69,70</sup>. Hotspot *TERT* promoter alterations were identified in 8 spitzoid melanomas (32%) and were more



common in spitzoid melanomas with a non-Spitz nevus MAPK activating mutation (Figure 7C).

Inactivation of the tumor suppressor *CDKN2A* is a major driver in melanoma, and homozygous deletion of *CDKN2A* may be associated with poor outcome in atypical Spitz tumors<sup>69,71</sup>. Bi-allelic loss of function of *CDKN2A* was identified in 5 (20%) spitzoid melanomas. In four cases, bi-allelic loss occurred by homozygous deletion of *CDKN2A*, and in the remaining case, there was a truncating mutation of *CDKN2A* with loss of the wild-type allele. Four of nine (44%) Spitz melanomas demonstrated bi-allelic inactivation of *CDKN2A*.

### Clinical Follow-Up

We were able to obtain clinical follow up data for 12 patients, 11 of whom were alive at the time of this study (Table 1, mean follow up 44 months). One patient died 60 months after excision from unknown causes. One patient (case 21) had multiple cutaneous recurrences beginning 26 months after excision. Another patient had a positive sentinel lymph node biopsy that was followed by completion lymphadenectomy with no record of relapse during follow-up. Nine patients were treated with simple excision all of which had an uneventful follow-up period.

### Discussion

The genetic alterations in our series of 25 spitzoid melanomas differed significantly from those reported for cutaneous melanomas. *BRAF*V600 mutations found in the majority of low-CSD cutaneous melanomas were completely absent, indicating that spitzoid melanomas do not typically arise from common acquired nevi. Instead we found an increased incidence (30%) of oncogenic alterations typical for Spitz tumors such as *HRAS* mutation and activating fusions *BRAF*, *MAP3K8*, *ALK*, and *NTRK1*.

The Spitz melanomas with *HRAS* mutation or *ALK* or *NTRK1* kinase fusion retained the some of the distinct histopathologic features associated with Spitz nevi with these mutations. Two of the Spitz melanomas had genetic features that indicate malignancy in low-and high-CSD melanoma (Cases 12 and 23). Two additional Spitz melanomas had bi-allelic inactivation of *CDKN2A*. Case 3 with an *NTRK1* fusion, but without other definitely pathogenic mutations demonstrated copy number loss upstream of *TERT*, suggesting a structural rearrangement. Similar rearrangements reactivate *TERT* in neuroblastoma and have been reported in lethal Spitz melanoma in the absence of a *TERT* promoter mutation<sup>13</sup>. By design, our targeted assay cannot detect structural rearrangements far upstream of *TERT* and therefore we may have missed similar alterations in other cases.

Most of our spitzoid melanomas were not classifiable as Spitz melanomas based on their genetic alterations. We further subdivided these ‘non-Spitz’ spitzoid melanomas into those without any identifiable MAP-kinase pathway mutations and those with MAPK pathway mutation(s) not associated with Spitz nevi such as in *NRAS*, *BRAF*, *KIT*, *NF1*, and or *MAP2K1/2*.

The melanomas in the latter of these two groups occurred in older patients, with more solar elastosis in the adjacent dermis and had a higher number of pathogenic mutations than the rest of our spitzoid melanomas, suggesting that they have a higher somatic mutation burden due to UV exposure. One notable exception was a spitzoid melanoma with focused high-level amplification of mutant *NRAS* that occurred on the ear of a teenager and demonstrated minimal solar elastosis and no additional pathogenic alterations. Focused high-level amplification of mutant *NRAS* has been described in spitzoid tumors on the ear of children<sup>72</sup>. Perhaps secondary amplification of mutant *NRAS* leads to spitzoid cytomorphologic features by a mechanism similar to *HRAS* mutation.

The different histopathologic features of conventional and Spitz nevi likely reflect differences in the oncogenic signaling outputs of their initiating mutations. Melanocytes of a conventional nevus may acquire secondary genetic alterations that lead to additional proliferation and a change in the cytomorphology of the neoplastic melanocytes. For example, when a melanocyte of a conventional nevus, which was initiated by a *BRAF* (or rarely *RAS*) mutation, acquires an activating *CTNNB1* mutation in addition to the mutation which initiated the nevus, a secondary clonal expansion of melanocytes characterized by increased cell size and pigmentation results in a component of deep penetrating nevus (melanocytoma)<sup>52</sup>. Bi-allelic loss of *BAP1* in a melanocyte of a conventional nevus results in a secondary proliferation of epithelioid melanocytes with distinctive spitzoid cytomorphology<sup>73–76</sup>. Similarly, bi-allelic loss of *PRKARIA* leads to development of a pigmented epithelioid melanocytoma within a conventional nevus<sup>77</sup>. While we identified a *CTNNB1* mutation in one spitzoid melanoma, we did not identify any pathogenic *BAP1* mutations in our series. This may indicate that cutaneous melanomas with *BAP1* loss are rare and represent only a small fraction of spitzoid melanoma, or that the spitzoid cytomorphologic features of melanocytic tumors with *BAP1* loss are not retained during malignant progression. Intriguingly, two spitzoid melanomas harbored activating *EZH2* mutations. Loss of *BAP1* has been shown to lead to increased *EZH2* activity and *EZH2*-dependent transformation<sup>78</sup>. Perhaps mutational activation of *EZH2* is functionally similar to loss of *BAP1* and also results in a spitzoid phenotype.

Most spitzoid melanomas without identified MAP-kinase pathway mutations occurred in young patients with little solar elastosis, similar to Spitz melanomas. Their genomes did not contain many deletions and amplifications suggesting they are distinct from “triple wild-type” melanomas in the TCGA that characteristically contain many copy number aberrations and structural rearrangements<sup>46</sup>. In one case we identified a *CRTC1-TRIM11* fusion which is not predicted to affect MAPK pathway signaling and has been recently described in dermal melanocytic tumors composed of epithelioid and spindled cells with minimal pigmentation that resemble clear cell sarcoma<sup>68</sup>. This case lacked melanin (pigmentation score of 0) and was characterized by epithelioid to spindled melanocytes with vesicular chromatin and a single prominent nucleolus, findings very characteristic of clear cell sarcoma.

Interestingly, our findings differ from those of the study performed by Lazova et al., in which the authors found a high genetic similarity between spitzoid and conventional melanomas with ~40% of the spitzoid melanomas in their series having a *BRAFV600*

mutation<sup>79</sup>. Perhaps the younger age of patients in our study accounts in part for the differences as the average age in our study was 45 years, whereas the average age in the study by Lazova et al. was 64 years. More likely, the disparate results may reflect different histopathologic criteria for spitzoid melanoma across institutions.

Our findings suggest that multiple evolutionary pathways can lead to spitzoid melanoma, and that it is not a homogeneous category. Given the genomic diversity of Spitz melanoma, and indeed the likelihood that spitzoid melanomas without Spitz initiating oncogenes are also genomically diverse, the failure of histopathologic criteria to distinguish all Spitz nevi from all spitzoid melanomas is not surprising. Diagnostic criteria likely need to be developed for each molecular sub-lineage (i.e. *ALK*-fused Spitz tumors, *HRAS* mutant Spitz tumors) and may need to include molecular as well as histopathologic findings. Future studies will aim to determine differences in clinical behavior for Spitz melanoma as compared to low- or high-CSD melanoma and the impact of specific initiating mutation, additional pathogenic mutations, and mutation burden on clinical outcomes.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank Connie Jang and Yvonne Lee for their assistance in organizing and obtaining the cases. Shyam Raghavan was funded in part by the American Society of Dermatopathology Mentorship Award, and Sandra Peternel was supported by a grant from the European Academy of Dermatology and Venereology (RF-2017-17). This work was supported by the National Cancer Institute at the National Institutes of Health (grant number 1R35CA220481).

## References

1. Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, “Spitzoid melanoma” and risk assessment. *Mod Pathol Off J U S Can Acad Pathol Inc* 2006;19 Suppl 2:S21–33.
2. Spitz S. Melanomas of Childhood. *Am J Pathol* 1948;24:591–609. [PubMed: 18859360]
3. Dika E, Fanti PA, Fiorentino M, Capizzi E, Neri I, Piraccini BM, et al. Spitzoid tumors in children and adults: a comparative clinical, pathological, and cytogenetic analysis. *Melanoma Res* 2015;25:295–301. [PubMed: 25933206]
4. Gerami P, Busam K, Cochran A, Cook MG, Duncan LM, Elder DE, et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. *Am J Surg Pathol* 2014;38:934–940. [PubMed: 24618612]
5. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of *HRAS* in Spitz nevi with distinctive histopathological features. *Am J Pathol* 2000;157:967–972. [PubMed: 10980135]
6. Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, et al. Recurrent *BRAF* kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. *Pigment Cell Melanoma Res* 2013;26:845–851. [PubMed: 23890088]
7. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. *Nat Commun* 2014;5:3116. [PubMed: 24445538]
8. Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, et al. Activating *MET* kinase rearrangements in melanoma and Spitz tumours. *Nat Commun* 2015;6:7174. [PubMed: 26013381]
9. Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, et al. *NTRK3* kinase fusions in Spitz tumours. *J Pathol* 2016;240:282–290. [PubMed: 27477320]


10. Wang L, Busam KJ, Benayed R, Cimera R, Wang J, Denley R, et al. Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms. *J Mol Diagn JMD* 2017;19:387–396. [PubMed: 28433076]
11. VandenBoom T, Quan VL, Zhang B, Garfield EM, Kong BY, Isales MC, et al. Genomic Fusions in Pigmented Spindle Cell Nevus of Reed: *Am J Surg Pathol* 2018;:1.
12. Quan VL, Zhang B, Mohan LS, Shi K, Isales MC, Panah E, et al. Activating Structural Alterations In MAPK Genes Are Distinct Genetic Drivers In a Unique Subgroup Of Spitzoid Neoplasms. *Am J Surg Pathol* 2019. doi:10.1097/PAS.0000000000001213.
13. Newman S, Fan L, Pribnow A, Silkov A, Rice SV, Lee S, et al. Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. *Nat Med* 2019;:1.
14. Busam KJ, Kutzner H, Cerroni L, Wiesner T. Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. *Am J Surg Pathol* 2014;38:925–933. [PubMed: 24698967]
15. Yeh I, de la Fouchardiere A, Pissaloux D, Mully TW, Garrido MC, Vemula SS, et al. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. *Am J Surg Pathol* 2015;39:581–591. [PubMed: 25602801]
16. Amin SM, Haugh AM, Lee CY, Zhang B, Bublely JA, Merkel EA, et al. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms. *Am J Surg Pathol* 2017;41:491–498. [PubMed: 27776007]
17. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. *Nat Genet* 2003;33:19–20. [PubMed: 12447372]
18. Yeh I, von Deimling A, Bastian BC. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. *J Natl Cancer Inst* 2013;105:917–919. [PubMed: 23690527]
19. Ackerman AB. *Spitz's Nevus: Reassessment Critical, Revision Radical*. New York: Ardor Scribendi, 2007.
20. Wu G, Barnhill RL, Lee S, Li Y, Shao Y, Easton J, et al. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. *Mod Pathol* 2016. doi:10.1038/modpathol.2016.37.
21. van Dijk MCRF, Bernsen MR, Ruiten DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. *Am J Surg Pathol* 2005;29:1145–1151. [PubMed: 16096402]
22. Fullen DR, Poynter JN, Lowe L, Su LD, Elder JT, Nair RP, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. *Mod Pathol Off J U S Can Acad Pathol Inc* 2006;19:1324–1332.
23. Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. *Br J Dermatol* 2009;161:364–372. [PubMed: 19438459]
24. Lazova R, Pornputtpong N, Halaban R, Bosenberg M, Bai Y, Chai H, et al. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas. *Mod Pathol* 2017. doi:10.1038/modpathol.2016.237.
25. Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. *Br J Dermatol* 2009;161:364–372. [PubMed: 19438459]
26. Elder DE, Massi D, Scolyer R, Willemze R. *WHO Classification of Skin Tumours*, 4th Edition. Lyon, France: IARC Press, 2018.
27. Paradela S, Fonseca E, Pita-Fernández S, Prieto V g. Spitzoid and non-spitzoid melanoma in children. A prognostic comparative study. *J Eur Acad Dermatol Venereol* 2013;27:1214–1221. [PubMed: 22928628]
28. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, et al. Improving melanoma classification by integrating genetic and morphologic features. *PLoS Med* 2008;5:e120. [PubMed: 18532874]
29. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, et al. MC1R Germline Variants Confer Risk for BRAF-Mutant Melanoma. *Science* 2006;313:521–522. [PubMed: 16809487]

30. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinforma Oxf Engl* 2009;25:1754–1760.
31. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–1303. [PubMed: 20644199]
32. Garrison, Gabor Erik M. Haplotype-based variant detection from short-read sequencing. arXiv 2012;1207.3907 [q-bio.GN].
33. Broad Institute. Picard. Available from: <http://broadinstitute.github.io/picard/>.
34. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38:e164–e164. [PubMed: 20601685]
35. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* 2012;28:i333–i339. [PubMed: 22962449]
36. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 2013;14:178–192. [PubMed: 22517427]
37. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. *PLOS Comput Biol* 2016;12:e1004873. [PubMed: 27100738]
38. Oesper L, Satas G, Raphael BJ. Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. *Bioinformatics* 2014;30:3532–3540. [PubMed: 25297070]
39. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res* 2016;44:D862–868. [PubMed: 26582918]
40. NHLBI GO Exome Sequencing Project (ESP). Exome Variant Server. Seattle, WA Available from: <http://evs.gs.washington.edu/EVS/>.
41. Consortium T 1000 GP. A global reference for human genetic variation. *Nature* 2015;526:nature15393.
42. Online Mendelian Inheritance in Man. OMM.McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). Available from: <https://omim.org>.
43. My Cancer Genome. Available from: <https://www.mycancergenome.org>.
44. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21. [PubMed: 23104886]
45. Nicorici D, atalan M, Edgren H, Kangaspeska S, Murumägi A, Kallioniemi O, et al. FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data. *bioRxiv* 2014;:011650.
46. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic Classification of Cutaneous Melanoma. *Cell* 2015;161:1681–1696. [PubMed: 26091043]
47. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. *Sci Signal* 2013;6:p11–p11. [PubMed: 23550210]
48. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. *Cancer Discov* 2012;2:401–404. [PubMed: 22588877]
49. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. *Nat Commun* 2014;5. doi:10.1038/ncomms5846.
50. Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, et al. Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations. *Mol Cancer Res MCR* 2019. doi:10.1158/1541-7786.MCR-19-0257.
51. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. *Blood* 2014;124:3007–3015. [PubMed: 25202140]

52. Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, et al. Combined activation of MAP kinase pathway and  $\beta$ -catenin signaling cause deep penetrating nevi. *Nat Commun* 2017;8:644. [PubMed: 28935960]
53. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Jin L-W, et al. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. *Acta Neuropathol (Berl)* 2016;132:757–760. [PubMed: 27624885]
54. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. *Science* 2013;339:957–959. [PubMed: 23348506]
55. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. *Science* 2013;339:959–961. [PubMed: 23348503]
56. Han S-Y, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, et al. Functional Evaluation of PTEN Missense Mutations Using in Vitro Phosphoinositide Phosphatase Assay. *Cancer Res* 2000;60:3147–3151. [PubMed: 10866302]
57. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. *Nat Genet* 2015;47:1411–1414. [PubMed: 26523776]
58. Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature* 2017;548:234. [PubMed: 28783719]
59. Nyström A-M, Ekvall S, Berglund E, Björkqvist M, Braathen G, Duchon K, et al. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. *J Med Genet* 2008;45:500–506. [PubMed: 18456719]
60. Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. *Hum Mol Genet* 2008;17:419–430. [PubMed: 17981815]
61. Gos M, Smigiel R, Kaczan T, Landowska A, Abramowicz A, Sasiadek M, et al. MAP2K2 mutation as a cause of cardio-facio-cutaneous syndrome in an infant with a severe and fatal course of the disease. *Am J Med Genet A* 2018;176:1670–1674. [PubMed: 29799162]
62. Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu J-Y, Paulk J, et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. *Nat Med* 2016;22:632–640. [PubMed: 27135738]
63. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807–1812. [PubMed: 18772396]
64. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 $\alpha$ . *Science* 2009;324:261–265. [PubMed: 19359588]
65. Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. *Nat Genet* 2015;47:1194–1199. [PubMed: 26343386]
66. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. *J Clin Oncol* 2006;24:4340–4346. [PubMed: 16908931]
67. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. *Nat Genet* 2012;44:133–139.
68. Cellier L, Perron E, Pissaloux D, Karanian M, Haddad V, Alberti L, et al. Cutaneous Melanocytoma With CRTCI-TRIM11 Fusion: Report of 5 Cases Resembling Clear Cell Sarcoma. *Am J Surg Pathol* 2018;42:382–391. [PubMed: 29240581]
69. Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, et al. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. *Sci Rep* 2015;5:11200. [PubMed: 26061100]
70. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, et al. TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. *J Natl Cancer Inst* 2014;106:dju246. [PubMed: 25217772]




71. Gerami P, Scolyer RA, Xu X, Elder DE, Abraham RM, Fullen D, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. *Am J Surg Pathol* 2013;37:676–684. [PubMed: 23388126]
72. Dubruc E, Balme B, Dijoud F, Disant F, Thomas L, Wang Q, et al. Mutated and amplified NRAS in a subset of cutaneous melanocytic lesions with dermal spitzoid morphology: report of two pediatric cases located on the ear. *J Cutan Pathol* 2014;41:866–872. [PubMed: 25263998]
73. Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, et al. A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression. *Am J Surg Pathol* 2012;36:818–830. [PubMed: 22367297]
74. Busam KJ, Sung J, Wiesner T, von Deimling A, Jungbluth A. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevocmelanocytes. *Am J Surg Pathol* 2013;37:193–199. [PubMed: 23026932]
75. Yeh I, Mully TW, Wiesner T, Vemula SS, Mirza SA, Sparatta AJ, et al. Ambiguous melanocytic tumors with loss of 3p21. *Am J Surg Pathol* 2014;38:1088–1095. [PubMed: 24705312]
76. Vilain RE, McCarthy SW, Thompson JF, Scolyer RA. BAP1-inactivated spitzoid naevi. *Am J Surg Pathol* 2015;39:722.
77. Cohen JN, Joseph NM, North JP, Onodera C, Zembowicz A, LeBoit PE. Genomic Analysis of Pigmented Epithelioid Melanocytomas Reveals Recurrent Alterations in PRKAR1A, and PRKCA Genes. *Am J Surg Pathol* 2017;41:1333–1346. [PubMed: 28796000]
78. LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. *Nat Med* 2015;21:1344–1349. [PubMed: 26437366]
79. Lazova R, Pornputtpong N, Halaban R, Bosenberg M, Bai Y, Chai H, et al. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas. *Mod Pathol* 2017. doi:10.1038/modpathol.2016.237.



**Figure 1. Spitz melanomas with HRAS mutations share features with HRAS mutant Spitz nevi.** (A) Low power view of case 14 which contained an *HRAS*<sup>Q61R</sup> mutation. The melanoma is predominantly intradermal and has a broad distribution. (B) On higher power view, the melanocytes are epithelioid and pleomorphic and distributed as single cells and elongated nests in between dense sclerotic collagen bundles. Occasional intra-nuclear inclusions are noted. (C) Low power view of case 23 which contained an *HRAS*<sup>G12D</sup> mutation. The melanoma is predominantly intradermal and broader than it is deep. (D) On higher power, superficial melanocytes are irregularly pigmented and deeper within the dermis. Dermal melanocytes have scant cytoplasm and hyperchromatic nuclei.






**Figure 2. Histopathology of Spitz melanomas with *BRAF* fusions.**

(A) and (B) Case 12-- *NRFI-BRAF* fusion. Sections show a highly cellular tumor with a thin overlying epidermis. The growth pattern is predominantly syncytial and the lesion is composed of epithelioid and spindled melanocytes with vesicular nuclei. (C) and (D) Case 4-- *SOX6-BRAF* fusion with amplification of the fusion gene. The melanocytes show vesicular nuclei and prominent nucleoli with heterogeneous pigment. There is mild epidermal hyperplasia.






**Figure 3. Spitz melanoma with ALK fusion.**


(A) Low power view of case 7 with a *DCTN1-ALK* fusion. As is characteristic in melanomas with *ALK* fusions, there are large vertically oriented nests in the superficial dermis. (B) Medium power view shows fusiform melanocytes arrayed in irregularly sized dermal nests with discohesive melanocytes (arrow). (C) High power view shows epithelioid melanocytes and multiple dermal mitoses.





**Figure 4. Rosette-like structures in Spitz melanoma with *NTRK1* fusion.** Case 3--*TPM3-NTRK* fusion. (A) Low power view demonstrates a dome shaped lesion with mild epidermal thinning. (B) High power shows epithelioid to spindled melanocytes with rosette-like structures (arrows in B), a feature that can be seen in Spitz tumors with *NTRK1* fusions. (C) Mitotic figures in the deep dermis are easily recognized.






**Figure 5. Spitzoid melanoma with a class 3 BRAF mutation.**

(A) Low power view of case 19 which harbors *BRAF*<sup>D594G</sup> mutation along with *EZH2*<sup>Y646S</sup>, *BLM*<sup>W803\*</sup>, *MAP2K2*<sup>F57Y</sup> and TERT promoter mutations. The neoplasm is predominantly dermal and is composed of coalescing nests and sheets of large epithelioid melanocytes with a focally dense infiltrate of lymphocytes. (B) Medium power shows a predominantly nested architecture with numerous admixed lymphocytes. (C) Nuclei are pleomorphic with prominent nucleoli and brisk mitotic activity (arrows).





**Figure 6. Spitzoid melanomas with NRAS mutation.**

(A) Low power view of case 6 which harbors *NRAS*<sup>Q61H</sup> with high level focused amplification the mutant allele shows a dome shaped compound tumor with epidermal hyperplasia and clefting around nests of melanocytes in the superficial dermis. (B) The lesion is composed of epithelioid melanocytes with hyperchromatic nuclei, growing as nests and fascicles distributed between thickened sclerotic collagen bundles. (C) Whole genome copy number profile demonstrates *NRAS* amplification as well as loss of chromosome 1p distal to *NRAS* and gain of chromosome 1q. (D) Low power view of case 25—which harbors *NRAS*<sup>Q61K</sup>, *CTNNB1*<sup>G34I</sup>, *IDH1*<sup>R132C</sup>, and *NFKBIE* and *TERT* promoter mutations shows a nodular tumor that extends to the deep dermis. (E) The lesion is


predominantly composed of large epithelioid melanocytes with focal areas of small more nevoid cells, predominantly near the dermal-epidermal junction. (F) Many dermal mitoses are present (arrows).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 7. Genetic alterations in spitzoid melanomas.**

(A) Oncoplot highlighting the genetic landscape of spitzoid melanomas in our cohort, stratified by those with classical Spitz drivers, non-Spitz MAPK drivers, and those without an identifiable MAPK mutation. (B) Number of pathogenic mutations in each subset. (C) Proportion of cases with *TERT* promoter mutations. Note that those tumors with non-Spitz MAPK drivers demonstrated an increase in both the number of pathogenic mutations as well as *TERT* promoter mutations.

Table 1.

## Clinical and Histopathologic features of Spitzoid Melanomas.

CASE	AGE	SEX	SITE	EPIDERMAL HYPERPLASIA	EPIDERMAL EFFACEMENT	ULCERATION	KAMINO BODIES	PIGMENTATION (SCORE 0-4)	SOLAR ELASTOSIS	DERMAL MELANOCYTES (PER MM <sup>2</sup> )	CYTOLOGY	PLEOMORPHISM	BRESLOW DEPTH (MM)	DIAMETER (MM)	CLINICAL FOLLOW-UP
1	4	M	LOWER LEG	MILD	NO	NO	NO	1	0	2	EPITHELIOID	MODERATE TO SEVERE	6	2.9	
2	11	F	RIGHT ARM	YES	NO	NO	NO	3	0	1	EPITHELIOID, SPINDLED	MODERATE	1.8	7.5	
3	11	F	LEFT EAR	YES	YES	NO	NO	1	0	3	EPITHELIOID, SPINDLED	MILD TO MODERATE	1.1	2.2	No recurrence at 34 months
4	13	F	LEFT LATERAL CALF	NO	NO	NO	NO	3	0	0	EPITHELIOID, SPINDLED	MILD	N/A	N/A	
5	13	F	LEFT CHEEK	YES	NO	NO	NO	0	0	2	EPITHELIOID, SPINDLED	MILD	8.4	9.2	
6	16	M	LEFT POSTERIOR UPPER EAR RIM	YES	YES	NO	NO	2	0+	1	EPITHELIOID, SPINDLED	MILD	1.3	3.3	
7	23	F	LEFT MEDIAL THIGH	YES	YES	NO	NO	1	0	3	EPITHELIOID, SPINDLED	MODERATE	2.2	8.9	
8	26	F	LEFT CALF	YES	YES	NO	NO	1	1	1	EPITHELIOID, SPINDLED	MILD TO MODERATE	1.2	5.3	
9	27	M	RIGHT BUTTOCK	YES	NO	NO	NO	2	0	0	EPITHELIOID, SPINDLED	MILD	0.6	5.9	No recurrence at 48 months
10	34	M	RIGHT LATERAL LEG	YES	NO	NO	YES	3	0+	2	EPITHELIOID	MODERATE TO SEVERE	1.3	5.5	No recurrence at 36 months
11	39	M	RIGHT THIGH	YES	NO	NO	NO	0	2	0	EPITHELIOID	SEVERE	3.7	6.9	
12	47	F	LEFT KNEE	YES	YES	NO	NO	0	0+	8	SPINDLED	MILD	3.8	9.9	No recurrence at 31 months
13	49	M	RIGHT LOWER LEG	YES	NO	NO	YES	4	1	0	EPITHELIOID	SEVERE	0.7	5.5	Died after 60 months (unknown reason)
14	50	F	LEFT LEG	NO	NO	NO	NO	0	1	2	EPITHELIOID, SPINDLED	MODERATE	1.3	5.7	
15	52	F	RIGHT PROXIMAL FOREARM	YES	YES	NO	NO	1	2	0	EPITHELIOID	MODERATE	0.4	6.7	
16	55	M	LEFT LATERAL BACK	YES	NO	NO	NO	0	1+	0	EPITHELIOID, SPINDLED	MODERATE	0.7	7.9	
17	57	M	RIGHT CHEST	YES	YES	YES	NO	4	1	1	EPITHELIOID	SEVERE	0.9	8.5	
18	61	M	RIGHT THIGH	YES	YES	NO	NO	1	2-	2	EPITHELIOID, SPINDLED	MODERATE	1.9	4.4	No recurrence at 36 months, sentinel node negative
19	68	M	LEFT FOREARM	YES	YES	NO	NO	0	2+	5	EPITHELIOID	SEVERE	1.9	5.7	No recurrence at 57 months
20	68	M	RIGHT CHEEK	YES	YES	YES	NO	1	3	1	EPITHELIOID, SPINDLED	MODERATE	1.9	4.4	No recurrence at 34 months
21	69	M	LEFT POSTERIOR SHOULDER	YES	YES	NO	NO	4	1+	0	EPITHELIOID, SPINDLED	MILD TO MODERATE	1.1	5.5	Multiple cutaneous recurrences beginning 26 months after diagnosis
22	70	F	RIGHT ANTERIOR THIGH	YES	NO	NO	NO	4	1+	0	EPITHELIOID, SPINDLED	MODERATE	0.5	5.8	No recurrence at 54 months
23	75	F	RIGHT TRICEPS	NO	NO	NO	NO	3	2-	2	SPINDLED	MILD	1.1	3.8	
24	78	F	LEFT LATERAL THIGH	NO	YES	NO	NO	2	1-	4	EPITHELIOID	MODERATE	1.1	2.6	No recurrence at 13 months
25	80	F	RIGHT CHEEK	NO	YES	NO	NO	2	3	9	EPITHELIOID	MODERATE	5.2	9.8	Local lymph node metastasis detected after 1 month.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

CASE	AGE	SEX	SITE	EPIDERMAL HYPERPLASIA	EPIDERMAL EFFACEMENT	ULCERATION	KAMINO BODIES	PIGMENTATION (SCORE 0-4)	SOLAR ELASTOSIS	DERMAL MITOSES (PER MM <sup>2</sup> )	CYTOLOGY	PLEOMORPHISM	BRESLOW DEPTH (MM)	DIAMETER (MM)	CLINICAL FOLLOW-UP	
																underwent left neck dissection; No recurrence after 60 months